John E. Kao, CEO of Alignment Healthcare (ALHC), recently reported the indirect sale of 118,000 shares valued at approximately $2.06 million, according to an SEC Form 4 filing. This transaction, executed at around $17.48 per share, is below his recent median sell size of 180,000 shares and part of a pre-arranged trading plan established last November. Post-sale, Kao retains a significant stake, holding over 4.1 million shares directly and indirectly.
This sale is noteworthy in the context of Alignment Healthcare’s performance, which has seen substantial growth, with 2025 revenue reaching $3.95 billion—a 46% increase year-over-year. The company aims for continued double-digit membership growth and projects revenue between $5.1 billion and $5.2 billion for 2026. However, with thin margins, the focus remains on translating growth into profitability, a crucial factor for long-term investors.
For market professionals, Kao’s sale appears routine and unlikely to impact stock performance significantly. The key takeaway is that while growth remains strong, investors should monitor Alignment’s ability to enhance margins to ensure sustainable profitability.
Source: fool.com